Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P910001/S124

ELCA Coronary Atherectomy Catheters

Spectranetics Corp. · Decision date Feb 6, 2026

FDA DECISIONP910001/S124

What did the FDA approve?

FDA records P910001/S124 as a supplement to PMA P910001, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Feb 6, 2026.

FDA approval order statement

the use of alternate components in the adhesive supplied to Philips/Spectranetics for the sterile barrier of the packaging system
Regulatory pathway
PMA supplement
Supplement type
135 Review Track For 30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Feb 6, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P910001/S124
Regulatory pathway
PMA supplement
Product code
LPC
Decision code
APPR
Decision date
Feb 6, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: DEVICE, ANGIOPLASTY, LASER, CORONARY.

Product code
LPC
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P910001/S124 received

    Application receipt date recorded by FDA.

  2. P910001/S125 · Related supplement

    ELCA Coronary Atherectomy Catheters

  3. P910001/S124 · FDA decision

    135 Review Track For 30-Day Notice

  4. P910001/S126 · Related supplement

    ELCA Coronary Laser Atherectomy Catheters

Timeline entries are records held by MedtechLedger for P910001. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P910001

Product / regulatory recordCompanyPathwayDecision dateSource
Spectranetics Corp.PMA supplementDec 18, 2025FDA
Spectranetics Corp.PMA supplementAug 14, 2026FDA
Spectranetics Corp.PMA supplementAug 21, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Spectranetics Corp.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
9965 Federal Dr., Colorado Springs, CO, 80921

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records